AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
16 of 20/20 Biolabs's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Sep 16, 2026 | Sep 18, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 3, 2026 | Sep 10, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 2, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 18, 2026 | Aug 19, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 17, 2026 | Aug 17, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 14, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 5, 2026 | Aug 5, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 16, 2026 | Jul 22, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 1, 2026 | Jul 1, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | Aug 18, 2026 | Jun 23, 2026 | SEC EDGAR |
| Current report | 8-K | May 19, 2026 | May 26, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 20, 2026 | SEC EDGAR |
| Current report | 8-K | May 20, 2026 | May 20, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 23, 2026 | Apr 28, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 31, 2026 | Apr 1, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 31, 2026 | SEC EDGAR |